The effect of polymorphism on adjuvant tamoxifen in Asian breast cancer patients: a meta-analysis.

OBJECTIVE

To evaluate the effect of polymorphism (C 100C>T, rs1065852) on clinical outcomes of female Asian breast cancer patients with tamoxifen adjuvant treatment.

METHODS

Meta-analysis of retrospective cohort studies published in July 2017 was performed. Fifteen studies with 1,794 Asian breast cancer patients were included, using strict eligibility requirements. Associations of disease-free survival (DFS), overall survival (OS) and recurrence rate after tamoxifen intake, with polymorphism were investigated through random effects models.

RESULTS

polymorphism was found to have effect on DFS and recurrence rate in various comparison models, but not on overall survival in the female Asian breast cancer patients.

CONCLUSION

In conclusion, our meta-analysis suggests that significant association of / () genotype with poorer DFS and recurrence exists in female Asian breast cancer patients with tamoxifen 20 mg/day adjuvant treatment. In the future, large and well-designed studies are required to illustrate the interactions of genetic variants, including polymorphism and tamoxifen response on female breast cancer patients.